VK 2809
Alternative Names: MB-07811; VK-2809Latest Information Update: 26 Jul 2024
Price :
$50 *
At a glance
- Originator Metabasis Therapeutics
- Developer Duke University; Viking Therapeutics
- Class Antihyperlipidaemics; Obesity therapies; Organophosphorus compounds; Small molecules
- Mechanism of Action Thyroid hormone receptor beta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hypercholesterolaemia; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- No development reported Adrenoleucodystrophy; Glycogen storage disease type I
Most Recent Events
- 26 Jul 2024 Viking Therapeutics plans end-of-phase II meeting in Non-alcoholic staetohepatitis in fourth quarter of 2024
- 03 Jun 2024 Updated 52 weeks efficacy and adverse events data from a phase IIb VOYAGE trial in Non alcoholic steatohepatitis released by Viking therapeutics
- 26 Jan 2024 Viking therapeutics completes a phase IIb VOYAGE trial in Non alcoholic steatoheapatitis in USA, Puerto Rico, Mexico, France, Belgium (PO) (NCT04173065)